

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

Role of Estrogen and Stress on the Brain-Gut Axis

Yanyan Jiang¹, Beverley Greenwood-Van Meerveld^{2,3}, Anthony C. Johnson^{3,4}, R. Alberto Travagli^{1,*}

¹Department of Neural and Behavioral Sciences,
Penn State-College of Medicine, Hershey, PA

and

²Oklahoma Center for Neuroscience,
University of Oklahoma Health Science Center, Oklahoma City, OK

³VA Health Care System, Oklahoma City, OK

⁴Department of Neurology,
University of Oklahoma Health Science Center, Oklahoma City, OK

Running title: sex and stress on the brain-gut axis

* Corresponding author:

Dr. R. Alberto Travagli

Department of Neural and Behavioral Sciences

Penn State College of Medicine

500 University Drive

MC H109

Hershey, PA 17033

rtravagli@pennstatehealth.psu.edu

Introduction

52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88

The gastrointestinal (**GI**) tract performs the processes of digestion under semi-autonomous control of the enteric nervous system (**ENS**). Parasympathetic (vagal and pelvic) and sympathetic (thoracolumbar) pathways convey sensory information to the central nervous system (**CNS**) and modulate motility via descending brain-gut pathways impinging onto ENS neurons. Disorders of the brain-gut axis contribute to the development of functional gastrointestinal disorders (**FGID**), such as functional dyspepsia (**FD**) and irritable bowel syndrome (**IBS**), that involve altered motility and/or altered sensitivity (21).

Multiple epidemiological studies have established that the prevalence of FGID is higher among women (25). Although the exact pathophysiology is largely unknown, clinical evidence suggests that GI dysmotility, including impaired gastric accommodation, delayed gastric emptying, and gastric hypersensitivity contributes to FD symptoms (25). Women are more likely to report symptoms of FD, such as nausea, early satiety, bloating and both upper and lower abdominal pain, and meet diagnostic criteria for FGID, suggesting the involvement of circulating gonadal hormones, estrogen and progesterone (25). GI motility is decreased in women, including a shorter migrating motor complex, prolonged proximal gastric relaxation, altered distal gastric motor function, and attenuated postprandial antral contractions, during the follicular phase when estrogen levels are high (4). These observations suggest that circulating female hormones play a major role in the delayed gastric emptying observed in women, although the effects of the menstrual cycle on gastric emptying rate seem inconclusive, likely due to a disparity in measurement methodology as well as the size, age, and intrinsic variation of the selected sample (44, 46, 92). Notably, pre- as well as post-menopausal women receiving hormone therapy replacement have gastric emptying rates slower than that of post-menopausal women without hormone therapy, which is similar to that of age-matched men (46). Studies in animals have also shown that gastric emptying rates are slower in intact compared to ovariectomized females, and that estradiol administration delays gastric emptying and inhibits gastrointestinal motility (9, 19, 36). Conversely, testosterone, or androgens in general, do not appear to have any effect on GI motility, or gastric hypersensitivity (3, 19, 36).

Abdominal pain is one of the major symptoms in IBS patients (24). Clinical evidence suggests that patients with IBS exhibit abnormal bowel habits in part due to altered smooth muscle function, abnormal mucosal transport, and/or increased epithelial permeability (24). There is a strong sex-related bias in the prevalence of IBS, with a female to male ratio ranging from 2:1 to 4:1 in developed countries (16). The observed sex difference in the prevalence and severity of GI symptoms in IBS could be, at least in part, explained by circulating ovarian

89 hormones (65), since many symptoms, such as bloating, change in bowel habits, and
90 abdominal pain vary during the menstrual cycle and pain severity scores are reduced in IBS
91 patients following menopause (22, 39, 71). Furthermore, in rodent models, colonic sensitivity is
92 increased during proestrus and estrus, and diminished during diestrus or metestrus (37, 48),
93 while estrogen replacement in ovariectomized rats increases visceromotor response to
94 nociceptive stimuli (18, 47).

95

96

Brain-Gut Axis Regulation of Motility

97

98 The coordinated autonomic processes of the GI tract, from the lower esophagus to the
99 transverse colon, are under a prominent extrinsic, parasympathetic modulatory control. Upper
100 GI functions are regulated by the efferent vagus nerve, the output of which is controlled by
101 neurons of the dorsal vagal complex (**DVC**), consisting of the dorsal motor nucleus of the vagus
102 (**DMV**), the nucleus tractus solitarius (**NTS**), and the area postrema. Sensory signals from the
103 upper GI tract are relayed by afferent vagal fibers to the NTS, where they are integrated with
104 information from other CNS centers involved in the regulation of autonomic and homeostatic
105 functions. The integrated signal is then transmitted from the NTS to the efferent preganglionic
106 neurons of the DMV, which project to either cholinergic (excitatory) or non-adrenergic non-
107 cholinergic (**NANC**, inhibitory, mainly vasoactive intestinal peptide and nitric oxide, but also
108 ATP) post-ganglionic myenteric neurons (12, 32, 85).

109

110 NTS neurons project to the DMV primarily via GABA-ergic, glutamatergic, and
111 catecholaminergic synapses, with GABAergic inputs exerting the strongest influence on the
112 activity of gastric-projecting DMV neurons. Microinjection of the GABA_A receptor antagonist,
113 bicuculline, into the DVC increases gastric motility, for example, whereas microinjections of
114 glutamatergic or catecholaminergic antagonists have limited effects on gastric motility and tone
115 under basal conditions. Using a brainstem slice preparation, we and others have shown that
116 bicuculline increases the firing rate in the majority of DMV neurons, suggesting a robust
117 GABAergic synaptic input onto these neurons, which tonically regulates their excitability.
118 Notably, these GABAergic NTS-DMV synapses are not static, but undergo a great deal of
119 plastic changes that enable an appropriate response of vagally regulated gastric motility to
120 variable physiological and pathophysiological conditions. The vagal output that modulates
121 gastric motility, or smooth muscle contractility, is thus largely dependent on the activity of DMV
122 neurons. Both the intrinsic spontaneous pacemaking properties as well as the synaptic inputs to
123 the DMV neurons shape their excitability and by consequence, determine the vagal motor
124 output to the stomach (85). Lower GI motility is modulated by the parasympathetic fibers
125 originating in the pelvic ganglia that innervate the distal colon.

126 Both the upper and lower GI tract is also innervated by sympathetic fibers from the
127 prevertebral ganglia which project to the esophagus, stomach and proximal small intestine
128 (celiac ganglia), duodenum (superior mesenteric ganglia), and distal small intestine and colon
129 (inferior mesenteric ganglia). These ganglia play an essential role in the inhibition of motility, via
130 activation of presynaptic α_2 receptors (29).

131

132 *Brain-Gut Axis Regulation of Sensitivity*

133

134 Sensory information, including noxious somatic stimuli, visceral pain, and responses to
135 neuromodulators released from the enteric neurons, is detected by nociceptors located
136 throughout the layers of the GI tract (35). While vagal afferent fibers play a significant role in
137 upper GI pain signaling, the majority of nociceptive signaling occurs via thoracolumbar
138 sympathetic afferents (30). The nociceptive neurons have cell bodies located in the dorsal root
139 ganglia, and transmit the noxious signal to the dorsal horn of the spinal cord (2, 8). Ascending
140 fibers transmit pain signals to higher centers via various tracts, and is relayed by the thalamus
141 to cortical areas for localization of pain, and to limbic areas, such as the amygdala, insula and
142 nucleus accumbens, for the processing of the emotional component of pain (14). Descending
143 inhibitory brainstem pathways are activated by outputs from both the cortical and the limbic
144 systems in response to the pain signals, decreasing noxious signaling by inhibiting dorsal horn
145 neurons (38).

146

147 Chronic visceral pain is associated with sensitization that occurs in both peripheral sensory
148 receptors and in the neuronal network mediating pain responses in the brain. Peripheral
149 sensitization in response to injury or infection is associated with receptor activation by
150 inflammatory mediators, such as cytokines, chemokines, or prostaglandins, and/or algescic
151 chemicals such as bradykinin or histamine (75). The downstream signaling further sensitizes
152 visceral afferents via modification of existing cell-membrane receptors that increases excitability
153 of the afferent fibers as well as via changes in gene expression that leads to insertion of more or
154 different classes of receptors into the cell membrane. These changes in sensory neurons modify
155 the amount and pattern of neurotransmitters released within the dorsal horn of the spinal cord,
156 and amplifies pain signals via both increased centripetal synaptic transmission and decreased
157 descending inhibitory modulation (26).

158

159 In the brain, a similar mechanism to promote and maintain chronic pain can be evoked in
160 the thalamus and brainstem. Increased afferent nociceptive neurotransmission due to peripheral
161 or spinal sensitization leads to hypersensitivity and central remodeling in the thalamus, and
162 enhances signaling to the other cortical and limbic regions (74). The integration nuclei, including

163 prefrontal cortex, cingulate cortex, amygdala, and insula, are subsequently sensitized in
164 response to increased afferent stimulation, which can produce an enhanced negative emotional
165 response, and/or disrupt the descending inhibitory pathways (89).

166

167 *Estrogen Receptor Signaling and Expression*

168

169 The biological effects of estrogen are mediated through two subtypes of genomic/nuclear
170 receptors, estrogen receptor (**ER**) α and ER β , as well as membrane bound/non-genomic
171 receptors, G protein-coupled receptor 30 (**GPR30**)/G protein-coupled estrogen receptor 1
172 (**GPER**). The mechanisms of estrogen action involve a long-term, slow genomic effect via
173 actions at nuclear receptors, and a rapid, non-genome action via activation of membrane-bound
174 GPER receptors (40).

175 Estrogen receptors are expressed throughout the brain, including the hypothalamus,
176 amygdala and midbrain, all of which have been shown to send extensive projections to
177 preganglionic vagal neurons of the DMV, and, hence, modulate GI functions (12, 57, 63, 80).
178 Estrogen receptors are also expressed on the myenteric plexus of both rodents and humans (1,
179 58, 59, 90, 93).

180 Estrogen or its non-selective agonist, 17 β -estradiol, inhibit voltage-gated potassium
181 channels in CNS regions (23) as well as in the GI tract resulting in inhibition of smooth muscle
182 contractility in both stomach and colon (1, 59, 90, 93), and modulates synaptic transmission and
183 neuronal firing rate via actions on both glutamate and GABAergic transmission (45, 64, 70, 88).

184

185 *Estrogen Effect on GI Motility*

186

187 Recent evidence indicates that estrogen receptors are abundant in the brainstem neuronal
188 population, including NTS and DMV neurons, thus providing the neuroanatomical support for
189 the direct effect of estrogen on either the DMV membrane and/or the critical GABAergic
190 synapses between NTS and DMV, hence vagal efferent output to the stomach (76, 87).
191 Furthermore, estrogen promotes increased density of vagal afferent projections to the NTS (20),
192 suggesting that estrogen may also facilitate GABAergic neurotransmission to the gastric-
193 projecting neurons of the DMV, thereby decreasing their excitability and vagal efferent output to
194 the stomach. Additionally, direct administration of estrogen onto isolated gastric smooth muscle
195 decreases gastric contractions, likely via a cGMP-dependent nitric oxide (**NO**) production (1,
196 77). Importantly, such effects of estrogen are also sex-dependent, since the relaxation in
197 response to estrogen is greater in females compared to males (1).

198

199 In general, estrogen has been shown to delay colonic motility in in vivo and in vitro rodent
200 models via the release of NO (7, 58, 93). However, short-term sex hormone supplementation
201 and withdrawal in healthy post-menopausal women was not found to affect colonic transit,
202 suggesting the effects of estrogen on GI motility may be influenced by the dosage and timing of
203 hormonal exposure (31).

204

205

Estrogen Effect on GI Sensitivity

206

207 Estrogen receptors (ERs) are distributed at all levels of the visceral pain sensation
208 pathways, including the ENS, spinal cord, and the brain centers mediating pain responses (81).
209 In peripheral visceral afferent terminals, estrogen can modulate nociception by altering ion
210 channel opening and regulation of receptor expression. Furthermore, estrogen also activates
211 colonic tachykinin NK1 receptor and probably induces substance P release, in addition to
212 modulating inflammatory pathways, secretion, and barrier function (10, 61, 78). Intrathecal
213 administration of an ER α agonist increases the visceromotor behavioral response to colonic
214 distension in ovariectomized rats, suggesting an important role of spinal ER in mediating
215 visceral sensation (17, 47).

216

217 An emerging body of evidence suggests that estrogen modulates not only pain perception,
218 but also the processing of visceral information in the CNS. Brain imaging studies have shown
219 that, compared to men with IBS, women with IBS have increased activation in emotional
220 circuits, including the amygdala and locus coeruleus, in response to aversive visceral stimuli
221 (54, 55). Elevation of estrogen levels by implantation of estradiol in the amygdala has been
222 shown to increase visceromotor pain response to colorectal distension in ovariectomized rats
223 (67). Although the underlying mechanisms of the central estrogen actions have not been fully
224 investigated, several studies have suggested that estrogen may alter expression of specific
225 receptors related to pain signaling, such as the glucocorticoid receptor (**GR**) (73). The estrogen-
226 mediated mechanism may also involve opioid systems, as evidence suggests that estrogen can
227 promote μ -opioid receptor activation in several brain areas, such as the amygdala and bed
228 nucleus of the stria terminalis, related to pain processing (15).

229

230

Stress Modulation of GI Motility

231

232 Stress can be defined as a stimulus or event that challenges the physiological and
233 psychological homeostasis of an individual (27, 86). A rapid, appropriate response to stress is a
234 reflexive mechanism that allows for necessary adaptive processes of relatively brief duration to
235 maintain physiological homeostasis. Conversely, prolonged stress represents a more serious

236 challenge and requires more sustained modifications. Stressful situations promote a complex
237 and integrated re-arrangement of neuroendocrine and autonomic stress systems, including the
238 vagal neurocircuits that control GI motility (41, 80, 85). Stress activates the hypothalamic-
239 pituitary-adrenocortical (**HPA**) axis resulting in release of corticotrophin-releasing hormone
240 (**CRH**) from the paraventricular nucleus of the hypothalamus (**PVN**) and elevations in circulating
241 glucocorticoids. CRH release delays gastric emptying and inhibits gastric motility profoundly
242 through actions that involve vagal motoneurons in the DVC (57). Indeed, functional GI
243 disorders, including FD and IBS, are correlated highly with stress, and stressful situations trigger
244 and exacerbate GI symptoms in susceptible individuals (21, 28). A lack of resilience,
245 habituation, or adaptation to stress results in dysfunction of both stomach (delayed gastric
246 emptying) and colon (accelerated colonic motility) (6). The response of individuals to stress,
247 however, differs such that some individuals exhibit high level of resistance, whereas other
248 individuals show vulnerability, to stress. It is crucial and urgent to recognize and elucidate the
249 underlying mechanisms that determine the degree of stress resilience or susceptibility to enable
250 a better understanding of stress-associated GI-related dysfunctions.

251
252 Cumulative evidence strongly supports the anxiolytic and stress-attenuating effects of
253 oxytocin, including the restoration of impaired gastric and colonic motility by oxytocin. A series
254 of studies pioneered by Takahashi's group have highlighted the essential role of central oxytocin
255 in adaptive GI response following chronic repetitive stress (5, 6, 91). Furthermore, oxytocin is
256 involved in restoring the delayed gastric emptying and impaired gastric motility following acute
257 stress or chronic stress maladaptation (91). Although several beneficial effects of oxytocin on GI
258 motility is attributed to its action to reduce the expression and release of CRH in the PVN and,
259 by consequence, the prominent systemic effect on the HPA axis (13, 53, 68), one cannot
260 downplay the direct influence of hypothalamic oxytocin on vagal neurocircuits innervating the GI
261 tract. In fact, oxytocin projections from the PVN are present in the DVC at birth, and increase
262 markedly with age. In adult rats, oxytocin axons occur throughout the rostrocaudal extent of the
263 DVC, and appose closely to GI-projecting DMV neurons (60). This anatomical evidence
264 suggests that oxytocin may regulate the activity of vagal neurocircuits directly, thus influencing
265 the vagal output to the peripheral organs, including the GI tract (60). Indeed, upon its release
266 onto the brainstem vagal neurons, oxytocin excites DMV neurons, and inhibits glutamate, but
267 not GABAergic, neurotransmission resulting in gastric relaxation through the activation of a
268 postganglionic nitric oxide-mediated pathway (11, 42, 72).

269
270 It is important to note that the oxytocinergic connection from the PVN to the DVC undergoes
271 a high level of neuroplasticity in both morphology and physiology, especially in conditions
272 related to stressful stimuli. In naïve, non-stressed rats, oxytocin mediated modulation of

273 previously unresponsive NTS-DMV GABAergic neurotransmission is uncovered by pretreatment
274 with CRH. Furthermore, the gastric relaxation induced by microinjection of oxytocin into the
275 DVC is attenuated, abolished, or even reversed in CRH-exposed rats, possible via a cAMP-
276 dependent translocation of oxytocin receptors to the terminals of GABAergic NTS-DMV
277 synapses. Interestingly, following stress load, the mechanism of action of oxytocin engages
278 another distinct pathway; in fact, in naïve conditions, the oxytocin-mediated effects occur via
279 activation of a NANC-NO pathway, while after stress, they involve the activation of
280 postganglionic VIP- and cholinergic- vagal pathways (11, 42).

281

282 Furthermore, we demonstrated recently that rats that undergo chronic repetitive stress
283 display a higher number of oxytocin-IR neurons that project from the PVN to the DVC, as well
284 as an increased density of oxytocin-IR fibers in the DVC (50). Such an upregulation of oxytocin
285 in the hypothalamic-vagal neurocircuits may contribute to stress adaptation and restoration of GI
286 motility, although its precise physiological effect and the modulation by sex hormones need
287 further investigation.

288 Although the mechanisms of neuroplasticity in vagal neurocircuits induced by chronic stress
289 are still largely unknown, the receptor translocation seems to be one important candidate that
290 can explain the rearrangement of brainstem wiring that determines the level of adaptive
291 response following chronic stress exposure. Indeed, we have shown recently that following
292 chronic stress exposure, the response of vagal neurocircuits to α 2-adrenergic activation
293 varies according to the type of chronic stress. Rats which underwent chronic variable stress
294 showed a larger inhibition of antrum tone in response to α 2-adrenergic activation, compared
295 to control or rats which underwent chronic repetitive stress. The translocation of α 2-
296 adrenergic receptor on GABAergic terminal of NTS-DMV synapses, combined with changes in intrinsic
297 DMV neuronal excitability, may be responsible for the maladaptive response to α 2-adrenergic
298 activation on gastric tone and motility (49). More detailed investigations on the mechanisms of
299 neuroplasticity of vagal neurocircuits occurred following chronic stress, as well as how these
300 changes contribute to the adaptive or maladaptive response to stress, are certainly needed.

301

302

Stress Modulation of GI Sensitivity

303

304 Stress maladaptation and negative emotions also play a significant role in the modulation of
305 colorectal hypersensitivity, which contributes to IBS. Clinically, evidence implicates that periods
306 of stress exhibit a high comorbidity with anxiety, depression, and other psychiatric disorders in
307 the exacerbation of IBS symptoms.

308

309 An emerging body of evidence has shown that stress enhance visceral hypersensitivity
310 through multifactorial mechanisms, e.g. psychological stress increases colonic permeability,
311 epithelial secretion, and the structure and composition of the ENS, likely via CRH1 mediated
312 actions (56, 69, 80).

313

314 In addition to peripheral mechanisms that mediated stress-induced visceral hypersensitivity,
315 activation of central neuroendocrine and pain facilitatory mechanisms by stress appears to play
316 a prominent role in colonic hypersensitivity (34). Neuroimaging studies in IBS patients have
317 shown a greater response to nociceptive stimuli in limbic regions (62) that regulate sensory
318 processing and emotion. In particular, several studies have suggested that neuronal remodeling
319 in the CeA following chronic stress exposure exacerbates nociception and promotes visceral
320 hypersensitivity (34). This neuronal remodeling involves regulation of CRH expression as well
321 as the corticosterone (**CORT**) receptors, mineralocorticoid (**MR**) and GR. Chronic stress or
322 stereotaxic delivery of CORT in the CeA induces visceral hypersensitivity, which can be
323 attenuated by central application of GR or MR antagonist to the CeA (66), or systemic
324 administration of a GR antagonist (43). Furthermore, a persistent decrease in GR expression in
325 the CeA and an upregulation of CRH has also been observed following visceral hypersensitivity
326 induced by either stress or CeA administration of CORT (33, 82, 83). Selectively knockdown of
327 GR or MR in the absence of CORT exposure in the CeA is sufficient to promote visceral
328 hypersensitivity in stress-naïve rats, indicating a significant role of GR and MR signaling in the
329 CeA for modulation of colonic sensitivity (51). In addition, CRH expression in the CeA is a
330 further regulator in mediating stress-induced visceral hypersensitivity. Indeed, intra-CeA CRH
331 administration increases colonic sensitivity via CRH₁ receptor activation, and similar findings
332 were demonstrated in female rats that had undergone an early life stressor (73) (79).
333 Knockdown of CRH in the CeA attenuates visceral hypersensitivity induced by adult or early life
334 stress, as does exposure of CeA to elevated CORT (52, 73). Furthermore, recent evidence also
335 suggests stress-induced visceral hypersensitivity involves central epigenetic mechanisms within
336 the CeA (82, 84).

337

338 *Summary and Conclusion*

339

340 The incidence of FGIDs is disproportionately higher in women, possibly due to a complex
341 interaction between sex hormone signaling and stress reactivity on the function of the brain-gut
342 axis. Specifically, both preclinical and clinical evidence has demonstrated that estrogen can
343 affect GI motility and sensitivity via direct activation of its receptors, which are located
344 throughout the brain-gut axis, and indirectly via modulation of other receptor systems. Many
345 women with FGIDs have also experienced multiple stressors across their lifespan, the additive

346 effects of which can lead to peripheral and central sensitization along the brain-gut axis to affect
347 motility and sensitivity throughout the GI tract. By further investigating sex- or stress-specific
348 mechanisms underlying FGID pathophysiology, targeted therapies can be developed to provide
349 relief for these patient populations.
350

351

352 **Figure 1: The effect of estrogen or stress in the brain-gut axis.** The brain-gut axis,
353 illustrated on the left of the figure, is comprised of bidirectional communication from the visceral
354 organs to the brain, via spinal and parasympathetic connections. Within the stress and pain
355 responsive areas in the brain, such as the amygdala (AMY), cingulate cortex (CING),
356 hippocampus (HIP), and hypothalamus (HYPO) integrate signals from the gastrointestinal (GI)
357 tract are transmitted through brainstem areas such as the dorsal vagal complex (DVC). The
358 bidirectional communication is relayed and modified within parasympathetic ganglia, such as the
359 nodose ganglia (NG), and/or sympathetic dorsal root ganglia (DRG), with further regulation of
360 noxious signals within the dorsal horn of the spinal cord. Within the GI tract, the stomach and
361 small intestine (Sm. Intest.) are primarily innervated by vagal afferents, while the majority of the
362 large intestine (Lg. Intest.) is innervated by spinal afferents. For each region of the brain-gut
363 axis, the summarized effect of estrogen signaling or stress on sensation (sen) or motility (mot) is
364 indicated with up arrows (↑) for increased responses, down arrows (↓) for decreased responses,
365 or both arrows (↕) when the response can both increase and decrease depending on the
366 receptor subtype. Changes are measured compared to ovariectomized females for estrogen or
367 non-stressed baselines for stress. A (--) indicates that there is no literature consensus on the
368 effect at the listed region.

369 Brain and GI images modified from CNX OpenStax / Wikimedia Commons / CC-BY-4.0.
370 https://commons.wikimedia.org/wiki/File:Figure_35_03_06.jpg and
371 https://commons.wikimedia.org/wiki/File:GI_normal.jpg

372

373

Acknowledgements

374 We thank Cesare M. and Zoraide Travagli for support and encouragement, and Dr. Kirsteen N.
375 Browning for comments on previous versions of the manuscript.

376 This work was supported by National Institute of Health grants # DK 99350 and DK 120170 to
377 Dr. Travagli.

378 Dr. Greenwood-Van Meerveld is a Senior Research Career Scientist with the Department of
379 Veterans Affairs (IK6-BX003610).

380 Dr. Johnson is a Career Development Award Fellow with the Department of Veterans Affairs
381 (IK2-BX003630).

382 The material in this review does not represent the views of the U.S. Department of Veteran
383 Affairs or the United States Government.

384 Yanyan Jiang, Beverly Greenwood-Van Meerveld, Anthony C. Johnson, and R. Alberto Travagli:
385 drafted the article or revised it critically for important intellectual content.

386

- 390 1. **Al-Shboul OA, Nazzal MS, Mustafa AG, Al-Dwairi AN, Alqudah MA, Abu Omar A,**
391 **Alfaqih MA, and Alsalem MI.** Estrogen relaxes gastric muscle cells via a nitric oxide- and cyclic
392 guanosine monophosphate-dependent mechanism: A sex-associated differential effect. *Exp*
393 *Ther Med* 16: 1685-1692, 2018.
- 394 2. **Almeida TF, Roizenblatt S, and Tufik S.** Afferent pain pathways: a neuroanatomical
395 review. *Brain Res* 1000: 40-56, 2004.
- 396 3. **Aloisi AM, Affaitati G, Ceccarelli I, Fiorenzani P, Lerza R, Rossi C, Pace MC,**
397 **Chiefari M, Aurilio C, and Giamberardino MA.** Estradiol and testosterone differently affect
398 visceral pain-related behavioural responses in male and female rats. *Eur J Pain* 14: 602-607,
399 2010.
- 400 4. **Aytug N, Giral A, Imeryuz N, Enc FY, Bekiroglu N, Aktas G, and Ulusoy NB.** Gender
401 influence on jejunal migrating motor complex. *Am J Physiol Gastrointest Liver Physiol* 280:
402 G255-G263, 2001.
- 403 5. **Babygirija R, Bulbul M, Yoshimoto S, Ludwig K, and Takahashi T.** Central and
404 peripheral release of oxytocin following chronic homotypic stress in rats. *Auton Neurosci* 167:
405 56-60, 2012.
- 406 6. **Babygirija R, Zheng J, Bulbul M, Cerjak D, Ludwig K, and Takahashi T.** Sustained
407 delayed gastric emptying during repeated restraint stress in oxytocin knockout mice. *J*
408 *Neuroendocrinol* 22: 1181-1186, 2010.
- 409 7. **Baumgartner C, Hubacher T, Kraymer M, and Gschossmann J.** In vitro spontaneous
410 contractile activity of colonic smooth muscle in naive Lewis rats: Acute effect of gonadal
411 hormones. *J Dig Dis* 18: 13-22, 2017.
- 412 8. **Besson JM and Chaouch A.** Peripheral and spinal mechanisms of nociception. *Physiol*
413 *Rev* 67: 67-186, 1987.
- 414 9. **Bond EF, Heitkemper MM, and Perigo R.** Gastric emptying and gastric-intestinal
415 transit in rats with varying ovarian hormone status. *Nurs Res* 45: 218-224, 1996.
- 416 10. **Bradesi S, Eutamene H, Garcia-Villar R, Fioramonti J, and Bueno L.** Stress-induced
417 visceral hypersensitivity in female rats is estrogen-dependent and involves tachykinin NK1
418 receptors. *Pain* 102: 227-234, 2003.
- 419 11. **Browning KN, Babic T, Toti L, Holmes GM, Coleman FH, and Travagli RA.** Plasticity
420 in the brainstem vagal circuits controlling gastric motor function triggered by corticotropin
421 releasing factor. *J Physiol* 592: 4591-4605, 2014.

- 422 12. **Browning KN and Travagli RA.** Central nervous system control of gastrointestinal
423 motility and secretion and modulation of gastrointestinal functions. *Compr Physiol* 4: 1339-1368,
424 2014.
- 425 13. **Bulbul M, Babygirija R, Cerjak D, Yoshimoto S, Ludwig K, and Takahashi T.**
426 Hypothalamic oxytocin attenuates CRF expression via GABA(A) receptors in rats. *Brain Res*
427 1387: 39-45, 2011.
- 428 14. **Bushnell MC, Ceko M, and Low LA.** Cognitive and emotional control of pain and its
429 disruption in chronic pain. *Nat Rev Neurosci* 14: 502-511, 2013.
- 430 15. **Cairns BE and Gazerani P.** Sex-related differences in pain. *Maturitas* 63: 292-296,
431 2009.
- 432 16. **Canavan C, West J, and Card T.** The epidemiology of irritable bowel syndrome. *Clin*
433 *Epidemiol* 6: 71-80, 2014.
- 434 17. **Cao DY, Bai G, Ji Y, and Traub RJ.** Epigenetic upregulation of metabotropic glutamate
435 receptor 2 in the spinal cord attenuates oestrogen-induced visceral hypersensitivity. *Gut* 64:
436 1913-1920, 2015.
- 437 18. **Chaloner A and Greenwood-Van Meerveld B.** Sexually dimorphic effects of
438 unpredictable early life adversity on visceral pain behavior in a rodent model. *J Pain* 14: 270-
439 280, 2013.
- 440 19. **Chen TS, Doong ML, Chang FY, Lee SD, and Wang PS.** Effects of sex steroid
441 hormones on gastric emptying and gastrointestinal transit in rats. *Am J Physiol* 268: G171-176,
442 1995.
- 443 20. **Ciriello J and Caverson MM.** Effect of estrogen on vagal afferent projections to the
444 brainstem in the female. *Brain Res* 1636: 21-42, 2016.
- 445 21. **Drossman DA.** Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical
446 Features and Rome IV. *Gastroenterology*, 2016.
- 447 22. **Drossman DA, Chang L, Bellamy N, Gallo-Torres HE, Lembo A, Mearin F, Norton**
448 **NJ, and Whorwell P.** Severity in irritable bowel syndrome: a Rome Foundation Working Team
449 report. *Am J Gastroenterol* 106: 1749-1759, 2011.
- 450 23. **Druzin M, Malinina E, Grimsholm O, and Johansson S.** Mechanism of estradiol-
451 induced block of voltage-gated K⁺ currents in rat medial preoptic neurons. *PLoS One* 6:
452 e20213, 2011.
- 453 24. **Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, Niesler B, Quigley**
454 **EM, Rajilic-Stojanovic M, Schemann M, Schwille-Kiuntke J, Simren M, Zipfel S, and Spiller**
455 **RC.** Irritable bowel syndrome. *Nat Rev Dis Primers* 2: 16014, 2016.
- 456 25. **Enck P, Azpiroz F, Boeckxstaens G, Elsenbruch S, Feinle-Bisset C, Holtmann G,**
457 **Lackner JM, Ronkainen J, Schemann M, Stengel A, Tack J, Zipfel S, and Talley NJ.**
458 Functional dyspepsia. *Nat Rev Dis Primers* 3: 17081, 2017.

- 459 26. **Fornasari D.** Pain mechanisms in patients with chronic pain. *Clin Drug Investig* 32 Suppl
460 1: 45-52, 2012.
- 461 27. **Franklin TB, Saab BJ, and Mansuy IM.** Neural mechanisms of stress resilience and
462 vulnerability. *Neuron* 75: 747-761, 2012.
- 463 28. **Fukudo S.** Stress and visceral pain: focusing on irritable bowel syndrome. *Pain* 154
464 Suppl 1: S63-70, 2013.
- 465 29. **Furness JB.** The enteric nervous system and neurogastroenterology. *Nat Rev*
466 *Gastroenterol Hepatol* 9: 286-294, 2012.
- 467 30. **Gebhart GF and Bielefeldt K.** Physiology of Visceral Pain. *Compr Physiol* 6: 1609-
468 1633, 2016.
- 469 31. **Gonenne J, Esfandyari T, Camilleri M, Burton DD, Stephens DA, Baxter KL,**
470 **Zinsmeister AR, and Bharucha AE.** Effect of female sex hormone supplementation and
471 withdrawal on gastrointestinal and colonic transit in postmenopausal women.
472 *Neurogastroenterol Motil* 18: 911-918, 2006.
- 473 32. **Goyal RK, Guo Y, and Mashimo H.** Advances in the physiology of gastric emptying.
474 *Neurogastroenterol Motil* 31: e13546, 2019.
- 475 33. **Greenwood-Van Meerveld B, Gibson M, Gunter W, Shepard J, Foreman R, and**
476 **Myers D.** Stereotaxic delivery of corticosterone to the amygdala modulates colonic sensitivity in
477 rats. *Brain Res* 893: 135-142, 2001.
- 478 34. **Greenwood Van-Meerveld B and Johnson AC.** Mechanisms of Stress-induced
479 Visceral Pain. *J Neurogastroenterol Motil* 24: 7-18, 2018.
- 480 35. **Grundy D.** Neuroanatomy of visceral nociception: vagal and splanchnic afferent. *Gut* 51
481 Suppl 1: i2-5, 2002.
- 482 36. **Gual O, Bozkurt A, Deniz M, Sungur M, and Yegen BC.** Effect of sex steroids on
483 colonic distension-induced delay of gastric emptying in rats. *J Gastroenterol Hepatol* 19: 975-
484 981, 2004.
- 485 37. **Gustafsson JK and Greenwood-Van Meerveld B.** Amygdala activation by
486 corticosterone alters visceral and somatic pain in cycling female rats. *Am J Physiol Gastrointest*
487 *Liver Physiol* 300: G1080-1085, 2011.
- 488 38. **Heinricher MM, Tavares I, Leith JL, and Lumb BM.** Descending control of nociception:
489 Specificity, recruitment and plasticity. *Brain Res Rev* 60: 214-225, 2009.
- 490 39. **Heitkemper MM, Cain KC, Jarrett ME, Burr RL, Hertig V, and Bond EF.** Symptoms
491 across the menstrual cycle in women with irritable bowel syndrome. *Am J Gastroenterol* 98:
492 420-430, 2003.
- 493 40. **Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M,**
494 **Strom A, Treuter E, Warner M, and Gustafsson JA.** Estrogen receptors: how do they signal
495 and what are their targets. *Physiol Rev* 87: 905-931, 2007.


- 496 41. **Herman JP and Tasker JG.** Paraventricular Hypothalamic Mechanisms of Chronic
497 Stress Adaptation. *Front Endocrinol (Lausanne)* 7: 137, 2016.
- 498 42. **Holmes GM, Browning KN, Babic T, Fortna SR, Coleman FH, and Travagli RA.**
499 Vagal afferent fibres determine the oxytocin-induced modulation of gastric tone. *J Physiol* 591:
500 3081-3100, 2013.
- 501 43. **Hong S, Zheng G, Wu X, Snider NT, Owyang C, and Wiley JW.** Corticosterone
502 mediates reciprocal changes in CB 1 and TRPV1 receptors in primary sensory neurons in the
503 chronically stressed rat. *Gastroenterology* 140: 627-637 e624, 2011.
- 504 44. **Horowitz M, Maddern GJ, Chatterton BE, Collins PJ, Petrucco OM, Seamark R, and**
505 **Shearman DJ.** The normal menstrual cycle has no effect on gastric emptying. *Br J Obstet*
506 *Gynaecol* 92: 743-746, 1985.
- 507 45. **Hu P, Liu J, Yasrebi A, Gotthardt JD, Bello NT, Pang ZP, and Roepke TA.** Gq
508 Protein-Coupled Membrane-Initiated Estrogen Signaling Rapidly Excites Corticotropin-
509 Releasing Hormone Neurons in the Hypothalamic Paraventricular Nucleus in Female Mice.
510 *Endocrinology* 157: 3604-3620, 2016.
- 511 46. **Hutson WR, Roehrkasse RL, and Wald A.** Influence of gender and menopause on
512 gastric emptying and motility. *Gastroenterology* 96: 11-17, 1989.
- 513 47. **Ji Y, Bai G, Cao DY, and Traub RJ.** Estradiol modulates visceral hyperalgesia by
514 increasing thoracolumbar spinal GluN2B subunit activity in female rats. *Neurogastroenterol Motil*
515 27: 775-786, 2015.
- 516 48. **Ji Y, Tang B, and Traub RJ.** The visceromotor response to colorectal distention
517 fluctuates with the estrous cycle in rats. *Neuroscience* 154: 1562-1567, 2008.
- 518 49. **Jiang Y, Browning KN, Toti L, and Travagli RA.** Vagally mediated gastric effects of
519 brain stem alpha2-adrenoceptor activation in stressed rats. *Am J Physiol Gastrointest Liver*
520 *Physiol* 314: G504-G516, 2018.
- 521 50. **Jiang Y, Coleman FH, Kopenhaver Doheny K, and Travagli RA.** Stress Adaptation
522 Upregulates Oxytocin within Hypothalamo-Vagal Neurocircuits. *Neuroscience* 390: 198-205,
523 2018.
- 524 51. **Johnson AC and Greenwood-Van Meerveld B.** Knockdown of steroid receptors in the
525 central nucleus of the amygdala induces heightened pain behaviors in the rat.
526 *Neuropharmacology* 93: 116-123, 2015.
- 527 52. **Johnson AC, Tran L, and Greenwood-Van Meerveld B.** Knockdown of corticotropin-
528 releasing factor in the central amygdala reverses persistent viscerosomatic hyperalgesia. *Transl*
529 *Psychiatry* 5: e517, 2015.
- 530 53. **Jurek B and Neumann ID.** The Oxytocin Receptor: From Intracellular Signaling to
531 Behavior. *Physiol Rev* 98: 1805-1908, 2018.

- 532 54. **Labus JS, Dinov ID, Jiang Z, Ashe-McNalley C, Zamanyan A, Shi Y, Hong JY,**
533 **Gupta A, Tillisch K, Ebrat B, Hobel S, Gutman BA, Joshi S, Thompson PM, Toga AW, and**
534 **Mayer EA.** Irritable bowel syndrome in female patients is associated with alterations in
535 structural brain networks. *Pain* 155: 137-149, 2014.
- 536 55. **Labus JS, Gupta A, Coveleskie K, Tillisch K, Kilpatrick L, Jarcho J, Feier N, Bueller**
537 **J, Stains J, Smith S, Suyenobu B, Naliboff B, and Mayer EA.** Sex differences in emotion-
538 related cognitive processes in irritable bowel syndrome and healthy control subjects. *Pain* 154:
539 2088-2099, 2013.
- 540 56. **Lauffer A, Vanuytsel T, Vanormelingen C, Vanheel H, Salim Rasoel S, Toth J, Tack**
541 **J, Fornari F, and Farre R.** Subacute stress and chronic stress interact to decrease intestinal
542 barrier function in rats. *Stress* 19: 225-234, 2016.
- 543 57. **Lewis MW, Hermann GE, Rogers RC, and Travagli RA.** In vitro and in vivo analysis of
544 the effects of corticotropin releasing factor on rat dorsal vagal complex. *J Physiol* 543: 135-146,
545 2002.
- 546 58. **Li Y, Xu J, Jiang F, Jiang Z, Liu C, Li L, Luo Y, Lu R, Mu Y, Liu Y, and Xue B.** G
547 protein-coupled estrogen receptor is involved in modulating colonic motor function via nitric
548 oxide release in C57BL/6 female mice. *Neurogastroenterol Motil* 28: 432-442, 2016.
- 549 59. **Liu JYH, Lin G, Fang M, and Rudd JA.** Localization of estrogen receptor ERalpha,
550 ERbeta and GPR30 on myenteric neurons of the gastrointestinal tract and their role in motility.
551 *Gen Comp Endocrinol* 272: 63-75, 2019.
- 552 60. **Llewellyn-Smith IJ, Kellett DO, Jordan D, Browning KN, and Travagli RA.** Oxytocin-
553 immunoreactive innervation of identified neurons in the rat dorsal vagal complex.
554 *Neurogastroenterol Motil* 24: e136-146, 2012.
- 555 61. **Looijer-van Langen M, Hotte N, Dieleman LA, Albert E, Mulder C, and Madsen KL.**
556 Estrogen receptor-beta signaling modulates epithelial barrier function. *Am J Physiol Gastrointest*
557 *Liver Physiol* 300: G621-626, 2011.
- 558 62. **Mayer EA, Labus JS, Tillisch K, Cole SW, and Baldi P.** Towards a systems view of
559 IBS. *Nat Rev Gastroenterol Hepatol* 12: 592-605, 2015.
- 560 63. **McEwen BS, Akama KT, Spencer-Segal JL, Milner TA, and Waters EM.** Estrogen
561 effects on the brain: actions beyond the hypothalamus via novel mechanisms. *Behav Neurosci*
562 126: 4-16, 2012.
- 563 64. **Mukherjee J, Cardarelli RA, Cantaut-Belarif Y, Deeb TZ, Srivastava DP, Tyagarajan**
564 **SK, Pangalos MN, Triller A, Maguire J, Brandon NJ, and Moss SJ.** Estradiol modulates the
565 efficacy of synaptic inhibition by decreasing the dwell time of GABAA receptors at inhibitory
566 synapses. *Proc Natl Acad Sci U S A* 114: 11763-11768, 2017.
- 567 65. **Mulak A, Tache Y, and Larauche M.** Sex hormones in the modulation of irritable bowel
568 syndrome. *World J Gastroenterol* 20: 2433-2448, 2014.


- 569 66. **Myers B and Greenwood-Van Meerveld B.** Differential involvement of amygdala
570 corticosteroid receptors in visceral hyperalgesia following acute or repeated stress. *Am J*
571 *Physiol Gastrointest Liver Physiol* 302: G260-266, 2012.
- 572 67. **Myers B, Schulkin J, and Greenwood-Van Meerveld B.** Sex steroids localized to the
573 amygdala increase pain responses to visceral stimulation in rats. *J Pain* 12: 486-494, 2011.
- 574 68. **Neumann ID, Wigger A, Torner L, Holsboer F, and Landgraf R.** Brain oxytocin
575 inhibits basal and stress-induced activity of the hypothalamo-pituitary-adrenal axis in male and
576 female rats: partial action within the paraventricular nucleus. *J Neuroendocrinol* 12: 235-243,
577 2000.
- 578 69. **Nozu T, Miyagishi S, Kumei S, Nozu R, Takakusaki K, and Okumura T.** Lovastatin
579 inhibits visceral allodynia and increased colonic permeability induced by lipopolysaccharide or
580 repeated water avoidance stress in rats. *Eur J Pharmacol* 818: 228-234, 2018.
- 581 70. **Oberlander JG and Woolley CS.** 17beta-Estradiol Acutely Potentiates Glutamatergic
582 Synaptic Transmission in the Hippocampus through Distinct Mechanisms in Males and
583 Females. *J Neurosci* 36: 2677-2690, 2016.
- 584 71. **Palsson OS, Whitehead WE, Barghout V, Levy R, Field A, Von Korff M, Garner M,**
585 **Drossman DA, and Turner MJ.** IBS severity and health-related quality of life improve with age
586 in women but not in men. *Am J Gastroenterol* 98: S272, 2003.
- 587 72. **Peters JH, McDougall SJ, Kellett DO, Jordan D, Llewellyn-Smith IJ, and Andresen**
588 **MC.** Oxytocin enhances cranial visceral afferent synaptic transmission to the solitary tract
589 nucleus. *J Neurosci* 28: 11731-11740, 2008.
- 590 73. **Prusator DK and Greenwood-Van Meerveld B.** Amygdala-mediated mechanisms
591 regulate visceral hypersensitivity in adult females following early life stress: importance of the
592 glucocorticoid receptor and corticotropin-releasing factor. *Pain* 158: 296-305, 2017.
- 593 74. **Saab CY.** Pain-related changes in the brain: diagnostic and therapeutic potentials.
594 *Trends Neurosci* 35: 629-637, 2012.
- 595 75. **Schaible HG, Ebersberger A, and Natura G.** Update on peripheral mechanisms of
596 pain: beyond prostaglandins and cytokines. *Arthritis Res Ther* 13: 210, 2011.
- 597 76. **Schlenker EH and Hansen SN.** Sex-specific densities of estrogen receptors alpha and
598 beta in the subnuclei of the nucleus tractus solitarius, hypoglossal nucleus and dorsal vagal
599 motor nucleus weanling rats. *Brain Res* 1123: 89-100, 2006.
- 600 77. **Shah S, Nathan L, Singh R, Fu YS, and Chaudhuri G.** E2 and not P4 increases NO
601 release from NANC nerves of the gastrointestinal tract: implications in pregnancy. *Am J Physiol*
602 *Regul Integr Comp Physiol* 280: R1546-1554, 2001.
- 603 78. **Straub RH.** The complex role of estrogens in inflammation. *Endocr Rev* 28: 521-574,
604 2007.

- 605 79. **Su J, Tanaka Y, Muratsubaki T, Kano M, Kanazawa M, and Fukudo S.** Injection of
606 corticotropin-releasing hormone into the amygdala aggravates visceral nociception and induces
607 noradrenaline release in rats. *Neurogastroenterol Motil* 27: 30-39, 2015.
- 608 80. **Tache Y, Larauche M, Yuan PQ, and Million M.** Brain and Gut CRF Signaling:
609 Biological Actions and Role in the Gastrointestinal Tract. *Curr Mol Pharmacol* 11: 51-71, 2018.
- 610 81. **Ter Horst GJ, Wichmann R, Gerrits M, Westenbroek C, and Lin Y.** Sex differences in
611 stress responses: focus on ovarian hormones. *Physiol Behav* 97: 239-249, 2009.
- 612 82. **Tran L, Chaloner A, Sawalha AH, and Greenwood Van-Meerveld B.** Importance of
613 epigenetic mechanisms in visceral pain induced by chronic water avoidance stress.
614 *Psychoneuroendocrinology* 38: 898-906, 2013.
- 615 83. **Tran L and Greenwood-Van Meerveld B.** Altered expression of glucocorticoid receptor
616 and corticotropin-releasing factor in the central amygdala in response to elevated
617 corticosterone. *Behav Brain Res* 234: 380-385, 2012.
- 618 84. **Tran L, Schulkin J, Ligon CO, and Greenwood-Van Meerveld B.** Epigenetic
619 modulation of chronic anxiety and pain by histone deacetylation. *Mol Psychiatry* 20: 1219-1231,
620 2015.
- 621 85. **Travagli RA and Anselmi L.** Vagal neurocircuitry and its influence on gastric motility.
622 *Nat Rev Gastroenterol Hepatol* 13: 389-401, 2016.
- 623 86. **Ulrich-Lai YM and Herman JP.** Neural regulation of endocrine and autonomic stress
624 responses. *Nat Rev Neurosci* 10: 397-409, 2009.
- 625 87. **Vanderhorst VG, Gustafsson JA, and Ulfhake B.** Estrogen receptor-alpha and -beta
626 immunoreactive neurons in the brainstem and spinal cord of male and female mice:
627 relationships to monoaminergic, cholinergic, and spinal projection systems. *J Comp Neurol* 488:
628 152-179, 2005.
- 629 88. **Wang L, Burger LL, Greenwald-Yarnell ML, Myers MG, Jr., and Moenter SM.**
630 Glutamatergic Transmission to Hypothalamic Kisspeptin Neurons Is Differentially Regulated by
631 Estradiol through Estrogen Receptor alpha in Adult Female Mice. *J Neurosci* 38: 1061-1072,
632 2018.
- 633 89. **Wilder-Smith CH.** The balancing act: endogenous modulation of pain in functional
634 gastrointestinal disorders. *Gut* 60: 1589-1599, 2011.
- 635 90. **Winborn WB, Sheridan PJ, and McGill HC, Jr.** Sex steroid receptors in the stomach,
636 liver, pancreas, and gastrointestinal tract of the baboon. *Gastroenterology* 92: 23-32, 1987.
- 637 91. **Zheng J, Babygirija R, Bulbul M, Cerjak D, Ludwig K, and Takahashi T.**
638 Hypothalamic oxytocin mediates adaptation mechanism against chronic stress in rats. *Am J*
639 *Physiol Gastrointest Liver Physiol* 299: G946-953, 2010.


- 640 92. **Zia JK and Heitkemper MM.** Upper Gastrointestinal Tract Motility Disorders in Women,
641 Gastroparesis, and Gastroesophageal Reflux Disease. *Gastroenterol Clin North Am* 45: 239-
642 251, 2016.
- 643 93. **Zielinska M, Fichna J, Bashashati M, Habibi S, Sibaev A, Timmermans JP, and**
644 **Storr M.** G protein-coupled estrogen receptor and estrogen receptor ligands regulate colonic
645 motility and visceral pain. *Neurogastroenterol Motil* 29, 2017.
- 646



	Estrogen	Stress
AMY	↑ sen	↑ sen
CING	↑ sen	↑ sen
DVC	↓↑ sen ↓ mot	--
HIP	↑ sen	↑ sen
HYPO	--	↑ sen



	Estrogen	Stress
NG	↓↑ mot	--
DRG	↑ sen	↑ sen



	Estrogen	Stress
Stomach	↓ mot	↑ sen ↓ mot
Sm. Intest.	↓ mot	↑ sen ↑ mot
Lg. Intest.	↓↑ sen ↓ mot	↑ sen ↑ mot

